Arctoris secures funding to advance novel robotic drug discovery platform

1 Oct 2019

Platform will enable scientists and biotechnology entrepreneurs worldwide to make discoveries faster and more efficiently,

Arctoris, a fully automated drug discovery platform for virtual and traditional biotechnology companies, pharmaceutical corporations and academia, has successfully closed a seed funding round of £3.2 million to advance its novel drug discovery offering.

Arctoris secures funding to advance novel robotic drug discovery platform

The funding will be used to further build out the company’s commercial operations and service portfolio, the latter of which enables customers to rapidly and accurately achieve drug discovery milestones from target identification to candidate characterisation, as well as dataset generation for artificial intelligence (AI/ML) model validation and training.

From its beginnings at the University of Oxford in 2016, Arctoris has established the world’s first fully automated, robotic laboratory dedicated to drug discovery, providing global drug discovery teams with on-demand access to a broad range of cellular, molecular and biochemical assays. The company’s automated system delivers high-quality data through standardised, pre-optimised and fully validated processes, while its innovative online portal makes it easy for researchers to plan, order and track their experiments from anywhere in the world.

The funding round was led by RT Partners and included angel investors Patrick Pichette and Vishal Gulati, as well as additional industry-recognised investors and advisors including Charles Songhurst, Alexander Straub, TD Veen AS and Tanarra Capital.

"At RT Partners, we invest in UK-based, IP-rich technology that has the potential to revolutionise the life science industry. Arctoris’s novel platform and compelling vision is perfectly aligned with this objective. The successful completion of this seed funding round will support the company’s clear potential to improve how drug discovery is planned and performed," said Alex Gough, Partner, RT Partners.

Martin-Immanuel Bittner, Chief Executive Officer and Co-Founder of Arctoris, commented: "This support from industry-recognised investors and advisors will enable our team to continue to develop our revolutionary approach to drug discovery, which has been specifically designed to produce data of the highest possible quality from a broad range of biochemical, molecular biology and cell biology assays. Through our platform, scientists and biotechnology entrepreneurs worldwide can make discoveries faster and more efficiently, paving the way to introducing new treatments to patients sooner."

"At a practical level, this funding will enable us to further advance our technology, expand our service offering, attract more leading experts to join our thriving team and support the imminent opening of our new, bespoke laboratory facility. It will also allow us to continue to be closely involved in BioTarget, the world’s first biotech competition for emerging companies dedicated to finding new molecules for cancer treatment," said Tom Fleming MChem, Chief Operating Officer and Co-Founder of Arctoris.

Read More

Related news

Funding to accelerate delivery of Univercells' vaccine portfolio

Funding to accelerate delivery of Univercells' vaccine portfolio

11 Oct 2019

European financing to support Univercells’ R&D investments to develop four essential and undersupplied global health vaccines to be produced at affordable prices, high quality and large volumes.

Read more 
Industrial-scale manufacture of therapeutic exosomes

Industrial-scale manufacture of therapeutic exosomes

10 Oct 2019

Coordinated purification process development service accelerates progress to clinical trials, and scale-up manufacturing.

Read more 
BASF and Biomillenia join forces in microbiome research to promote healthy skin

BASF and Biomillenia join forces in microbiome research to promote healthy skin

7 Oct 2019

Research aims to identify novel dermocosmetic active ingredients via unique microbiome-on-a-chip technology.

Read more 
Data on lead ADC demonstrates effective tumour regression

Data on lead ADC demonstrates effective tumour regression

1 Oct 2019

IKS01 shows marked anti-tumour efficacy in pre-clinical models of ovarian and lung cancer.

Read more 
Researchers develop less toxic anti-cancer drug

Researchers develop less toxic anti-cancer drug

24 Sep 2019

New drug works like a ‘magic bullet’ that is delivered directly to the mitochondria of cancer cells.

Read more 
EC approves its first plant-derived cannabis-based medicine

EC approves its first plant-derived cannabis-based medicine

24 Sep 2019

Epidyolex (cannabidiol) approved for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy.

Read more 
Study demonstrates potential of blood test for early lung cancer detection

Study demonstrates potential of blood test for early lung cancer detection

16 Sep 2019

Ground-breaking trial demonstrates potential of blood test which harnesses the power of the immune system to reduce late detection of lung cancer.

Read more 
M2i Life Sciences completes a historic fundraising of 60 million Euros

M2i Life Sciences completes a historic fundraising of 60 million Euros

16 Sep 2019

To support its strong growth, M2i Life Sciences has concluded a capital increase of 60 million Euros with five leading investors (ADM Capital, Eurazeo Growth, Téthys Invest, Creadev and France 2i fund managed by RAISE Impact).

Read more 
FUJIFILM Irvine Scientific launches BalanCD Gal Supplement for biotherapeutic development

FUJIFILM Irvine Scientific launches BalanCD Gal Supplement for biotherapeutic development

10 Sep 2019

Delivers enhanced galactosylation for improved protein quality, and antibody binding and function.

Read more 
BioCity backs world's first Rx to OTC switch incubator

BioCity backs world's first Rx to OTC switch incubator

5 Sep 2019

Maxwellia considered to have the skills and the expertise to deliver and reach their goal of creating the big OTC brands of the future.

Read more